Orphazyme Financials
| ORPHA Stock | DKK 1,075 19.60 1.79% |
Orphazyme |
Understanding current and past Orphazyme Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Orphazyme's financial statements are interrelated, with each one affecting the others. For example, an increase in Orphazyme's assets may result in an increase in income on the income statement.
The data published in Orphazyme's official financial statements usually reflect Orphazyme's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Orphazyme AS. For example, before you start analyzing numbers published by Orphazyme accountants, it's critical to develop an understanding of what Orphazyme's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Orphazyme's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Orphazyme's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Orphazyme's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Orphazyme AS. Please utilize our Beneish M Score to check the likelihood of Orphazyme's management manipulating its earnings.
Orphazyme Stock Summary
Orphazyme competes with Ambu AS, Bavarian Nordic, Zealand Pharma, and . Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark.| Instrument | Denmark Stock View All |
| Exchange | Copenhagen Exchange |
| ISIN | DK0060910917 |
| Business Address | Ole MaalOees Vej |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.orphazyme.com |
| Phone | 45 39 17 82 72 |
| Currency | DKK - Danish Krone |
You should never invest in Orphazyme without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Orphazyme Stock, because this is throwing your money away. Analyzing the key information contained in Orphazyme's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Orphazyme Key Financial Ratios
Generally speaking, Orphazyme's financial ratios allow both analysts and investors to convert raw data from Orphazyme's financial statements into concise, actionable information that can be used to evaluate the performance of Orphazyme over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Orphazyme AS reports annually and quarterly.| Return On Equity | -4.87 | |||
| Return On Asset | -1.33 | |||
| Target Price | 108.0 |
Orphazyme Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Orphazyme's current stock value. Our valuation model uses many indicators to compare Orphazyme value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Orphazyme competition to find correlations between indicators driving Orphazyme's intrinsic value. More Info.Orphazyme AS is regarded second in return on equity category among related companies. It is regarded second in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Orphazyme by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Orphazyme's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Orphazyme's earnings, one of the primary drivers of an investment's value.Orphazyme AS Systematic Risk
Orphazyme's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Orphazyme volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Orphazyme AS correlated with the market. If Beta is less than 0 Orphazyme generally moves in the opposite direction as compared to the market. If Orphazyme Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Orphazyme AS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Orphazyme is generally in the same direction as the market. If Beta > 1 Orphazyme moves generally in the same direction as, but more than the movement of the benchmark.
About Orphazyme Financials
What exactly are Orphazyme Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Orphazyme's income statement, its balance sheet, and the statement of cash flows. Potential Orphazyme investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Orphazyme investors may use each financial statement separately, they are all related. The changes in Orphazyme's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Orphazyme's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Orphazyme Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Orphazyme is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Orphazyme has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Orphazyme's financials are consistent with your investment objective using the following steps:- Review Orphazyme's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Orphazyme's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Orphazyme's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Orphazyme's stock is overvalued or undervalued.
Orphazyme April 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Orphazyme help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Orphazyme AS. We use our internally-developed statistical techniques to arrive at the intrinsic value of Orphazyme AS based on widely used predictive technical indicators. In general, we focus on analyzing Orphazyme Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Orphazyme's daily price indicators and compare them against related drivers.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 38.99 | |||
| Value At Risk | (5.47) | |||
| Potential Upside | 4.74 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orphazyme AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Orphazyme AS information on this page should be used as a complementary analysis to other Orphazyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Orphazyme Stock analysis
When running Orphazyme's price analysis, check to measure Orphazyme's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orphazyme is operating at the current time. Most of Orphazyme's value examination focuses on studying past and present price action to predict the probability of Orphazyme's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orphazyme's price. Additionally, you may evaluate how the addition of Orphazyme to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |